



Verastem to Present at Upcoming Conferences

May 8, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 8, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows:

- UBS Global Healthcare Conference on May 22, 2013, at 8:30am ET at the Sheraton New York Hotel in New York, NY
- Sachs Cancer BioPartnering Forum on May 22, 2013, at 10:30am ET at the Westin Copley Place in Boston, MA
- Deutsche Bank 38th Annual dbAccess Health Care Conference on May 29, 2013, at 4:50pm ET at the Westin Boston Waterfront Hotel in Boston, MA
- Marcum Microcap Conference on May 30, 2013, at 4:00pm ET at the Grand Hyatt Hotel in New York, NY

A webcast of the UBS, Deutsche Bank and Marcum conference presentations can be accessed by visiting the investors section of the Company's website at www.verastem.com. A replay of the webcasts will be archived on the Verastem website for two weeks following the presentation date.

About Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is discovering and developing drugs to treat cancer by the targeted killing of [cancer stem cells](#). Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Source: Verastem, Inc.

Verastem, Inc.

Brian Sullivan, 617-252-9314
bsullivan@verastem.com